Analysed KYOWA KIRIN CO LTD (KYKOF:OTCMKTS) News Sources
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
02-09-2026
yahoo.com
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC
09-09-2026
yahoo.com
Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)
29-09-2026
yahoo.com
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
29-09-2026
yahoo.com
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
30-09-2026
hospitalmanagement.net
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome
12-10-2026
yahoo.com
What is the current price of KYOWA KIRIN CO LTD (KYKOF:OTCMKTS)?
The current price of KYOWA KIRIN CO LTD (KYKOF:OTCMKTS) is $16.752.
KYOWA KIRIN CO LTD (KYKOF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of KYOWA KIRIN CO LTD (KYKOF:OTCMKTS) since the previous trading day is $1.352.
KYOWA KIRIN CO LTD (KYKOF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of KYOWA KIRIN CO LTD (KYKOF:OTCMKTS) since the previous trading day is 8.7792%.
What is the most recent average sentiment score for KYOWA KIRIN CO LTD (KYKOF:OTCMKTS)?
The most recent average sentiment score for KYOWA KIRIN CO LTD (KYKOF:OTCMKTS) is 63 out of 100.
What is the most recent average sentiment for KYOWA KIRIN CO LTD (KYKOF:OTCMKTS)?
The most recent sentiment for KYOWA KIRIN CO LTD (KYKOF:OTCMKTS) is .
SEC-8K** Filing Available For KYOWA KIRIN CO LTD (KYKOF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.